MedTrace Logo

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

NCT02855476 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2026-04-27

No results posted yet for this study

Summary

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.

Conditions

Sponsors & Collaborators

  • CHDI Foundation, Inc.

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Edward J Wild, MA, MB BChir, MRCP, PhD · University College, London

Eligibility

Min Age
11 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2027-04-30

Countries

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • New Zealand
  • Poland
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855476 on ClinicalTrials.gov